type in your search and press enter
OPKO Announces Positive Topline Results In Phase 2 Diabetes And Obesity Trial
You May Also Like
Preclinical Data Presented at American Association for Cancer Research (AACR) Annual Meeting Demonstrate Enhanced Therapeutic Benefit of Combining a PS-Targeting Antibody With Anti-PD-1 Therapy in Models of Triple Negative Breast Cancer (TNBC)
- Statistically Significant Improvement in Overall Survival for Combination as Compared to Anti-PD-1 Therapy ...
TiGenix: Transparency notifications pursuant to Article 14 of the Law of May 2, 2007
REGULATED INFORMATIONPRESS RELEASE Transparency notifications pursuant to Article 14 of the Law of May ...
Advanced Accelerator Applications Receives FDA Approval for Lutathera® for Treatment of Gastroenteropancreatic Neuroendocrine Tumors
Lutathera marks first FDA Approval for a Peptide Receptor Radionuclide Therapy (PRRT) Advanced ...
